Evidence map›Paper›PMID 27513973›Full record

ArticleCancer science2016

Fhit loss-associated initiation and progression of neoplasia in vitro.

Jenna R Karras, Morgan S Schrock, Bahadir Batar, Jie Zhang, Krista La Perle, Teresa Druck, Kay Huebner

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. The Clinical Relevance of Fragile Histidine Triad Protein (FHIT) in Patients with Bladder Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  4. Article
  5. Article
  6. Fhit down-regulation is an early event in pancreatic carcinogenesis.Virchows Archiv : an international journal of pathology · 2017
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jenna R KarrasDepartment of Cancer Biology and Genetics, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Morgan S SchrockDepartment of Cancer Biology and Genetics, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Bahadir BatarDepartment of Cancer Biology and Genetics, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Jie ZhangDepartment of Biomedical Informatics, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Krista La PerleDepartment of Veterinary Biosciences, College of Veterinary Medicine, Ohio State University, Columbus, Ohio, USA.
Teresa DruckDepartment of Cancer Biology and Genetics, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Kay HuebnerDepartment of Cancer Biology and Genetics, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
The Ohio State University Wexner Medical Center · USThe Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
Identifying non-coding RNAs for early detection and prevention of lung cancerU01CA166905 · NCI · OHIO STATE UNIVERSITY · PI CROCE, CARLO M, PASS, HARVEY IRA · 2013 to 2017
$4.5M
Wwox as a Critical Signal Mediator in Breast CancerR01CA120516 · NCI · OHIO STATE UNIVERSITY · PI HUEBNER, KAY · 2006 to 2013
$1.3M
NCI NIH HHS P30 CA016058NCI NIH HHS R01 CA120516NCI NIH HHS U01 CA166905
6 · The paper itself

Abstract

The FHIT gene, encompassing an active common fragile site, FRA3B, is frequently silenced in preneoplasia and cancer, through gene rearrangement or methylation of regulatory sequences. Silencing of Fhit protein expression causes thymidine kinase 1 downregulation, resulting in dNTP imbalance, and spontaneous replication stress that leads to chromosomal aberrations, allele copy number variations, insertions/deletions, and single-base substitutions. Thus, Fhit, which is reduced in expression in the majority of human cancers, is a genome "caretaker" whose loss initiates genome instability in preneoplastic lesions. To follow the early genetic alterations and functional changes induced by Fhit loss that may recapitulate the neoplastic process in vitro, we established epithelial cell lines from kidney tissues of Fhit-/- and +/+ mouse pups early after weaning, and subjected cell cultures to nutritional and carcinogen stress, which +/+ cells did not survive. Through transcriptome profiling and protein expression analysis, we observed changes in the Trp53/p21 and survivin apoptotic pathways in -/- cells, and in expression of proteins involved in epithelial-mesenchymal transition. Some Fhit-deficient cell lines showed anchorage-independent colony formation and increased invasive capacity in vitro. Furthermore, cells of stressed Fhit-/- cell lines formed s.c. and metastatic tumors in nude mice. Collectively, we show that Fhit loss and subsequent thymidine kinase 1 inactivation, combined with selective pressures, leads to neoplasia-associated alterations in genes and gene expression patterns in vitro and in vivo.

Indexed as

Disease ProgressionAcid Anhydride HydrolasesAnimalsApoptosisBis(5'-adenosyl)triphosphataseCell MovementCells, CulturedCell Transformation, NeoplasticEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticKidneyMaleMiceMice, Inbred C57BLNeoplasm MetastasisAcid Anhydride HydrolasesBis(5'-adenosyl)triphosphataseNeoplasm ProteinsThymidine Kinasethymidine kinase 1Cell transformationcommon fragile sitegenome instabilitykidney cell linestumorigenicity

Identifiers

PMID27513973
PMCPMC5132276
OpenAlexW2517580767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.